白敬宇品牌怎么样 申请店铺

我要投票 白敬宇在医疗用品行业中的票数:99 更新时间:2025-01-22
白敬宇是哪个国家的品牌?「白敬宇」是 南京白敬宇制药有限责任公司 旗下著名品牌。该品牌发源于江苏,由创始人陈在1991-07-12期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
白敬宇怎么样

南京白敬宇制药是一家生产化学原料药及制剂药的综合性制药公司,首批“中华老字号”和江苏省高新技术企业。公司前身“白敬宇眼药厂”1937年在南京成立,“白敬宇”商标于1939年注册,是中国为数极少的民国时期药品注册商标之一,2011年被国家工商总局认定为“中国驰名商标”。公司现有员工近800人,近三年累计产销和利税分别为12.67亿元和1.16亿元,2012年在岗员工人均可支配收入6.22万元。

公司原料药和制剂药生产基地分别位于六合化学工业园区和新港经济技术开发区,两个厂区绿树成荫,均为园区的“园林式工厂”,在2010-2011年先后通过了ISO9001质量体系认证、ISO14001环境管理体系认证以及ISO18001职业健康安全管理体系的认证,在同类企业中处于领先地位。

公司现有注册产品120个,其中原料药27个,制剂药93个。制剂药有片剂、膏剂、胶囊剂、散剂、酊剂、混悬液剂、凝胶剂等15个剂型,主要产品有心脑血管、祛痰镇咳、抗感染、维生素类、眼用膏剂等系列品种,有26个产品进入国家基本药物目录。主要剂型的年最大产量为:片剂80亿片,激素药20亿片,酊水100万升,膏剂6500万支,胶囊剂6.5亿粒,混悬剂45万升、洗剂5万升、散剂9000万包。公司另有24个品规的制剂药产品在12个国家取得了药品注册证书,产品销售到38个国家和地区。公司原料药常年生产盐酸左旋咪唑、酮康唑、氯霉素及酮酸钙等产品,年生产能力大于1000吨。原料药3个主要品种已在欧洲、美国、日本、俄罗斯等国注册销售。

公司的“国际合作”理念决定了公司对原料生产区的环保治理具有超前意识,按照国际惯例,客户在接受产品前必须对企业进行严格的全面质量审计,其中“人的安全和环境保护”是审计的重要项目,因此,供应商审计是公司能够不断进步的动力。2006年至今,原料药厂区共接受国外供应商审计20余次,其中有美国通用、比利时杨森、德国拜耳、西班牙因杜肯等国际性大公司,公司现已成为上述公司的产品供应商。

公司是南京市药品出口产量最大的企业,尤其是制剂药出口更是领先,自营出口1千万美元,出口供货值1亿元人民币。公司以“做好产品、卖好产品”为宗旨,致力于实业拓展。公司的目标是:到2014年,产品制造水平要达到国内一流、国际中等以上标准,以满足不同市场的客户需要,确保企业可持续发展。

Nanjing Baijingyu Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical company that produces chemical raw materials and pharmaceutical preparations. It is one of the first batch of "Chinese time-honored brands" and high-tech enterprises in Jiangsu Province. The company's predecessor, Bai Jingyu eye pharmaceutical factory, was established in Nanjing in 1937. The trademark of Bai Jingyu was registered in 1939. It is one of the few drug registered trademarks in the Republic of China. In 2011, it was recognized as "China's famous trademark" by the State Administration of industry and Commerce. The company has nearly 800 employees. In the past three years, the cumulative production and sales and profits and taxes are RMB 1.267 billion and RMB 116 million respectively. In 2012, the average disposable income of on-the-job employees is RMB 62200. The company's API and pharmaceutical production bases are respectively located in Liuhe chemical industry park and Xingang economic and Technological Development Zone. Both of the two plants are "garden type factories" in the park. From 2010 to 2011, they have passed ISO9001 quality system certification, ISO14001 environmental management system certification and ISO18001 occupational health and safety management system certification, and are in the leading position among similar enterprises First place. The company has 120 registered products, including 27 APIs and 93 pharmaceutical preparations. Preparations include tablets, ointments, capsules, powder, tincture, suspension, gel and other 15 formulations. The main products are cardiovascular, expectorant, antitussive, anti infective, vitamin, eye paste and other varieties. 26 products have entered the national essential drug list. The annual maximum production of main dosage forms is: 8 billion tablets, 2 billion hormone drugs, 1 million liters tincture water, 65 million plasters, 650 million capsules, 450000 liters suspension, 50000 liters lotion and 90 million packages powder. Another 24 pharmaceutical products of the company have obtained drug registration certificates in 12 countries, and the products have been sold to 38 countries and regions. The company's APIs produce levamisole hydrochloride, ketoconazole, chloramphenicol, calcium ketoacid and other products throughout the year, with an annual production capacity of more than 1000 tons. Three main varieties of APIs have been registered and sold in Europe, the United States, Japan, Russia and other countries. The company's concept of "international cooperation" determines that the company has an advanced awareness of environmental protection in the raw material production area. According to international practice, customers must conduct a strict overall quality audit on the enterprise before accepting products. Among them, "human safety and environmental protection" is an important audit project. Therefore, supplier audit is the driving force for the company to make continuous progress. Since 2006, the API plant area has been audited by foreign suppliers for more than 20 times, among which there are international large companies such as general motors of the United States, Janssen of Belgium, Bayer of Germany, induken of Spain, etc. the company has become the product supplier of the above companies. The company is the largest pharmaceutical export enterprise in Nanjing, especially the leading pharmaceutical export, with self export of US $10 million and export supply value of RMB 100 million. With the tenet of "do well in products and sell well in products", the company is committed to industrial development. The company's goal is: by 2014, the product manufacturing level should reach the domestic first-class, international medium-sized and above standards, so as to meet the needs of customers in different markets and ensure the sustainable development of the enterprise.

本文链接: https://brand.waitui.com/ba0510fe3.html 联系电话:02586504321

千城特选小程序码

7×24h 快讯

中科飞测:向特定对象发行A股股票申请获上交所受理

36氪获悉,中科飞测公告,公司于2025年1月22日收到上交所关于受理公司科创板上市公司发行证券申请的通知。上交所对公司报送的募集说明书及相关申请文件进行了核对,认为申请文件齐备,符合法定形式,决定予以受理并依法进行审核。公司本次向特定对象发行A股股票事项尚需通过上交所审核,并获得中国证监会同意注册的决定后方可实施。上述事项最终能否通过上交所审核,并获得中国证监会同意注册的决定及其时间尚存在不确定性。

58分钟前

*ST鹏博:公司股票可能被终止上市

36氪获悉,*ST鹏博公告,因中喜会计师事务所对公司出具了无法表示意见的《2023年度审计报告》,公司股票被实施退市风险警示。若公司2024年度财务会计报告被出具保留意见、无法表示意见或否定意见的审计报告以及财务报告内部控制被出具无法表示意见或者否定意见的审计报告,公司股票将被上海证券交易所决定终止上市。公司预计2024年年度归属于母公司所有者的净利润约为-7.75亿元,扣除非经常性损益后的净利润约为-7.36亿元。预计2024年年度实现营业收入约为18.87亿元。预计2024年年末归属于母公司净资产约为1.9亿元。

58分钟前

摩根大通美国国债客户多头占比创2023年以来新高

摩根大通美国国债客户调查显示,截至1月21日当周,多头占比上升2个百分点,至2023年12月4日以来的最高水平。净多头创同日以来新高,空头占比下降4个百分点,中性上升2个百分点。(界面)

58分钟前

美股大型科技股盘前多数上涨,奈飞涨超14%

36氪获悉,美股大型科技股盘前多数上涨,截至发稿,奈飞涨超14%,英伟达涨超3%,Meta、微软涨超1%,亚马逊涨0.72%,谷歌涨0.01%,特斯拉跌超1%,苹果跌0.24%。

58分钟前

热门中概股美股盘前多数下跌,理想汽车跌超2%

36氪获悉,热门中概股美股盘前多数下跌,截至发稿,理想汽车跌超2%,哔哩哔哩、腾讯音乐跌超1%,小鹏汽车跌0.93%,百度跌0.68%,阿里巴巴跌0.18%,拼多多跌0.12%,京东涨超1%,蔚来涨0.48%。

58分钟前

本页详细列出关于摩罗丹HANYAO的品牌信息,含品牌所属公司介绍,摩罗丹HANYAO所处行业的品牌地位及优势。
咨询